<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081795</url>
  </required_header>
  <id_info>
    <org_study_id>CR013681</org_study_id>
    <secondary_id>JNS019-JPN-02</secondary_id>
    <nct_id>NCT01081795</nct_id>
  </id_info>
  <brief_title>A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine</brief_title>
  <official_title>A Placebo-Controlled Dose-Finding Study of JNS019 (Topiramate) in Migraine Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a recommended dose of topiramate in participants
      with migraine (type of severe headache that occurs periodically and is often associated with
      nausea, vomiting, and constipation or diarrhea), to verify the superiority (statistically
      more effective) of the drug to placebo (an inactive substance that is compared with a drug to
      test whether the drug has a real effect in a clinical trial), and to assess if a same
      therapeutic effect can be observed between this study and overseas Caucasian clinical
      studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter (more than 1 site), placebo-controlled (compared to placebo),
      randomized (participants assigned study drug by chance), double-blind (neither the
      participant nor the physician know the assigned study drug), parallel-group comparison
      (comparison for each group at the same time) study. The study period consists of 4 phases:
      the observation phase, double-blind phase, exit period and follow-up period. After the
      double-blind phase, the participants will be transferred to the continuous treatment study.
      The observation phase which is started after informed consent consists of the washout period
      (non-treatment period with migraine preventive medication: at least 2 weeks) and baseline
      determination period (at least 4 weeks). The participants who complete the observation phase
      and meet the inclusion criteria will be randomly assigned to the topiramate 50 milligram (mg)
      group, topiramate 100-mg group or placebo group after registration. The double-blind phase
      consists of the titration period (dose-escalation, 4 weeks) and fixed-dose period (18 weeks).
      In the titration period, starting from 1 topiramate 25-mg tablet or 1 topiramate 25-mg
      placebo tablet once daily (1 tablet in the evening), the dose will be increased by 1 tablet
      every week up to twice daily (2 tablets in the morning, 2 tablets in the evening). After
      that, the twice-daily treatment (2 tablets in the morning, 2 tablets in the evening) will be
      continued for 7 days from Day 22 to Day 28. In the fixed-dose period, the topiramate 25-mg
      tablets or topiramate 25-mg placebo tablets at the same dose as that in the final treatment
      in titration period will be continued. The participants who are not transferred to the
      continuous treatment study after completion of the double-blind phase or after
      discontinuation during the double-blind phase will be transferred to the exit period (up to 1
      week).The participants who complete the exit period will be transferred to the follow-up
      period, and a follow-up of the participant's safety and headache symptoms such as the
      migraine period rate will be conducted for 4 weeks after the completion of investigational
      treatment. Meanwhile, the participants who complete the double-blind phase or those who
      discontinue the study at Week 4 or later in the fixed-dose period during the double-blind
      phase due to lack of efficacy and give consent to transfer to the continuous treatment study
      will be transferred to the transfer period (up to 3 weeks) under blind conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6</measure>
    <time_frame>Baseline (28 days before randomization) through Month 6</time_frame>
    <description>As per 24-hour rule, if symptom of pain due to migraine continues for more than 24 hours, it should be considered as 2 or more migraine attacks considering the maximum duration up to 24 hours. If the interval between latest migraine attack (ending time) and previous migraine attack (onset time) is less than 24 hours, 2 migraine attacks should be considered as 1 migraine attack. If the onset of migraine was prevented by a rescue drug, it should be considered as 1 migraine attack even if aura had started. Mean change was calculated by subtracting baseline value from the mean of 6 months value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6</measure>
    <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Migraine is a headache disorder with 2 subtypes: migraine without aura (at least 5 attacks lasting 4-72 hours with at least 2 following characteristics: unilateral location, pulsating quality, moderate/severe pain and either nausea/vomiting or photophobia and phonophobia) and migraine with aura (reversible focal neurological symptoms that develop over 5-20 minutes and last for less than 60 minutes); average at given month was calculated by dividing total number of migraine attack days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Number of Monthly Headache Days at Month 1, 2, 3, 4, 5 and 6</measure>
    <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Headache days were the days when at least 30-minute migraine and non-migraine headache occurred and were calculated from the headache diaries kept by the participants. Average at given month was calculated by dividing total number of headache days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Number of Monthly Migraine Attacks (According to the Diagnostic Criteria of the International Headache Society) at Month 1, 2, 3, 4, 5 and 6</measure>
    <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Migraine is a headache disorder with 2 subtypes: migraine without aura (at least 5 attacks lasting 4-72 hours with at least 2 following characteristics: unilateral location, pulsating quality, moderate/severe pain and either nausea/vomiting or photophobia and phonophobia) and migraine with aura (reversible focal neurological symptoms that develop over 5-20 minutes and last for less than 60 minutes); average at given month was calculated by dividing total number of migraine attacks until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monthly Migraine Attacks (According to 48-Hour Rule) at Month 1, 2, 3, 4, 5 and 6</measure>
    <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>As per 48-hour rule, if the symptom of pain due to migraine continues for more than 48 hours, it should be considered as 2 or more migraine attacks considering the maximum duration up to 48 hours. If the interval between the latest migraine attack (ending time) and the previous migraine attack (onset time) is less than 48 hours, the 2 migraine attacks should be considered as 1 migraine attack. If the onset of the migraine was prevented by a rescue drug, it should be considered as 1 migraine attack even if the aura had started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Migraine Attacks (According to 24-Hour Rule) Over Week 19 to Week 22 Period</measure>
    <time_frame>Baseline (28 days before randomization), Week 19 to Week 22 Period</time_frame>
    <description>The change from baseline in average number of migraine attacks (as per 24-hour rule) over Week 19 to Week 22 period was calculated by subtracting the baseline value from the average value of the Week 19 to Week 22 period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Rescue Drug Treatment Days</measure>
    <time_frame>Baseline (28 days before randomization)</time_frame>
    <description>Rescue medications are administered to participants when efficacy of study drug is not satisfactory, or effect of study drug is too great and is likely to cause a hazard to participant, or to manage an emergency situation. If an aura of migraine, a migraine attack or a non-migraine headache attack occurred during the study period, use of following rescue drugs was permitted: analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), ergotamines, triptans and anti-emetics (drug used to stop vomiting). Average at baseline was calculated by dividing total number of rescue drug treatment days until baseline by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Average Number of Rescue Drug Treatment Days at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Rescue medications are medicines that may be administered to the participants when efficacy of study drug is not satisfactory, or the effect of study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation. If an aura of migraine, a migraine attack or a non-migraine headache attack occurred during the study period, use of following rescue drugs was permitted: analgesics, NSAIDs, ergotamines, triptans and anti-emetics. Average at Month 6 was calculated by dividing total number of rescue drug treatment days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response to Study Treatment</measure>
    <time_frame>Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Responders were the participants who had at least 50 percent reduction in the average number of monthly migraine attacks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 Health Survey (SF-36) Score</measure>
    <time_frame>Baseline (28 days before randomization), Day 29, 85 and final evaluation (FE) (Day 155/early withdrawal [EW])</time_frame>
    <description>The SF-36 is a survey of participant health. It consists of 8 scaled scores, which are weighted sums of the questions in their section. The 8 sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. Each item is scored on a 0-100 range so that total score ranges from 0-100 with high score indicating more favorable health state. Final evaluation was done at Day 155 or at discontinuation for those participants who discontinued before Day 155.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">387</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Topiramate (JNS019) 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).</description>
    <arm_group_label>Topiramate (JNS019) 50 mg</arm_group_label>
    <arm_group_label>Topiramate 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).</description>
    <arm_group_label>Topiramate (JNS019) 50 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who meet the Second Edition of the International Classification of
             Headache Disorders (ICHD-II), 1.1 Migraine without aura or 1.2 Migraine with aura over
             at least 6 months before the time of informed consent

          -  Participants who had an average of no more than 8 migraine attacks per month during 3
             months before informed consent and an average of no more than 14 headache (migraine
             and non-migraine) days

          -  Participants whose number of migraine attacks during the baseline determination period
             (28 days) is 3 to 12 according to the 24-hour rule and number of headache days
             (migraine and non-migraine) is no more than 14

          -  Participants who took no migraine preventive medications over 2 weeks before informed
             consent, or who can take at least 2-week washout period before baseline determination
             period if they are taking migraine preventive medications

          -  Female participants must be postmenopausal, surgically sterile, abstinent, or can take
             adequate contraceptive measures after informed consent and continue it to the
             completion of investigational treatment

        Exclusion Criteria:

          -  Participants who cannot distinguish between migraine and non-migraine headache

          -  Participants with headache other than those described in the ICHD-II, 1.1 Migraine
             without aura, 1.2 Migraine with aura, 2. Tension headache or 11.5 Sinus headache

          -  If the participant has received drug therapies for prevention of migraine, the
             discontinued preventive therapies due to insufficient efficacy should be at least
             three types

          -  Participants who excessively took medications for migraine attacks such as analgesics
             (drug used to control pain) as medications to be taken as needed within 3 months
             before informed consent

          -  Participants who have taken topiramate (test drug in this study) in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bunkyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chitose</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iruma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamogawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suginami-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyonaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube N/A</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yonago N/A</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <results_first_submitted>March 19, 2013</results_first_submitted>
  <results_first_submitted_qc>March 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2013</results_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topiramate</keyword>
  <keyword>Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topiramate (JNS019) 50 mg</title>
          <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="P2">
          <title>Topiramate 100 mg</title>
          <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjectâ€™s schedule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Revocation of informed consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible for participation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of a prohibited concomitant drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Using drug with restricted days of use</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate (JNS019) 50 mg</title>
          <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="B2">
          <title>Topiramate 100 mg</title>
          <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="127"/>
            <count group_id="B4" value="387"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.4" spread="9.30"/>
                    <measurement group_id="B2" value="39.5" spread="9.25"/>
                    <measurement group_id="B3" value="41.2" spread="9.10"/>
                    <measurement group_id="B4" value="40.3" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6</title>
        <description>As per 24-hour rule, if symptom of pain due to migraine continues for more than 24 hours, it should be considered as 2 or more migraine attacks considering the maximum duration up to 24 hours. If the interval between latest migraine attack (ending time) and previous migraine attack (onset time) is less than 24 hours, 2 migraine attacks should be considered as 1 migraine attack. If the onset of migraine was prevented by a rescue drug, it should be considered as 1 migraine attack even if aura had started. Mean change was calculated by subtracting baseline value from the mean of 6 months value.</description>
        <time_frame>Baseline (28 days before randomization) through Month 6</time_frame>
        <population>Full analysis set (FAS) included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6</title>
          <description>As per 24-hour rule, if symptom of pain due to migraine continues for more than 24 hours, it should be considered as 2 or more migraine attacks considering the maximum duration up to 24 hours. If the interval between latest migraine attack (ending time) and previous migraine attack (onset time) is less than 24 hours, 2 migraine attacks should be considered as 1 migraine attack. If the onset of migraine was prevented by a rescue drug, it should be considered as 1 migraine attack even if aura had started. Mean change was calculated by subtracting baseline value from the mean of 6 months value.</description>
          <population>Full analysis set (FAS) included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Migraine attacks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="1.79"/>
                    <measurement group_id="O2" value="6.2" spread="2.11"/>
                    <measurement group_id="O3" value="6.6" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.50"/>
                    <measurement group_id="O2" value="-1.2" spread="2.72"/>
                    <measurement group_id="O3" value="-1.0" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1646</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square (LS) mean difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4479</p_value>
            <p_value_desc>ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6</title>
        <description>Migraine is a headache disorder with 2 subtypes: migraine without aura (at least 5 attacks lasting 4-72 hours with at least 2 following characteristics: unilateral location, pulsating quality, moderate/severe pain and either nausea/vomiting or photophobia and phonophobia) and migraine with aura (reversible focal neurological symptoms that develop over 5-20 minutes and last for less than 60 minutes); average at given month was calculated by dividing total number of migraine attack days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
        <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6</title>
          <description>Migraine is a headache disorder with 2 subtypes: migraine without aura (at least 5 attacks lasting 4-72 hours with at least 2 following characteristics: unilateral location, pulsating quality, moderate/severe pain and either nausea/vomiting or photophobia and phonophobia) and migraine with aura (reversible focal neurological symptoms that develop over 5-20 minutes and last for less than 60 minutes); average at given month was calculated by dividing total number of migraine attack days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.21"/>
                    <measurement group_id="O2" value="7.0" spread="2.35"/>
                    <measurement group_id="O3" value="7.3" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.93"/>
                    <measurement group_id="O2" value="-0.8" spread="3.75"/>
                    <measurement group_id="O3" value="-0.4" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.82"/>
                    <measurement group_id="O2" value="-1.1" spread="3.36"/>
                    <measurement group_id="O3" value="-0.7" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.74"/>
                    <measurement group_id="O2" value="-1.2" spread="3.27"/>
                    <measurement group_id="O3" value="-0.9" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.73"/>
                    <measurement group_id="O2" value="-1.3" spread="3.20"/>
                    <measurement group_id="O3" value="-1.0" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.76"/>
                    <measurement group_id="O2" value="-1.3" spread="3.22"/>
                    <measurement group_id="O3" value="-1.0" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.83"/>
                    <measurement group_id="O2" value="-1.3" spread="3.24"/>
                    <measurement group_id="O3" value="-1.0" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1547</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2624</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Number of Monthly Headache Days at Month 1, 2, 3, 4, 5 and 6</title>
        <description>Headache days were the days when at least 30-minute migraine and non-migraine headache occurred and were calculated from the headache diaries kept by the participants. Average at given month was calculated by dividing total number of headache days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
        <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Number of Monthly Headache Days at Month 1, 2, 3, 4, 5 and 6</title>
          <description>Headache days were the days when at least 30-minute migraine and non-migraine headache occurred and were calculated from the headache diaries kept by the participants. Average at given month was calculated by dividing total number of headache days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.39"/>
                    <measurement group_id="O2" value="7.4" spread="2.48"/>
                    <measurement group_id="O3" value="7.7" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.00"/>
                    <measurement group_id="O2" value="-0.8" spread="3.69"/>
                    <measurement group_id="O3" value="-0.4" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.88"/>
                    <measurement group_id="O2" value="-1.2" spread="3.33"/>
                    <measurement group_id="O3" value="-0.8" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.81"/>
                    <measurement group_id="O2" value="-1.3" spread="3.25"/>
                    <measurement group_id="O3" value="-0.9" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.81"/>
                    <measurement group_id="O2" value="-1.4" spread="3.15"/>
                    <measurement group_id="O3" value="-1.1" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.83"/>
                    <measurement group_id="O2" value="-1.4" spread="3.17"/>
                    <measurement group_id="O3" value="-1.2" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.89"/>
                    <measurement group_id="O2" value="-1.4" spread="3.18"/>
                    <measurement group_id="O3" value="-1.2" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2464</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3148</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Number of Monthly Migraine Attacks (According to the Diagnostic Criteria of the International Headache Society) at Month 1, 2, 3, 4, 5 and 6</title>
        <description>Migraine is a headache disorder with 2 subtypes: migraine without aura (at least 5 attacks lasting 4-72 hours with at least 2 following characteristics: unilateral location, pulsating quality, moderate/severe pain and either nausea/vomiting or photophobia and phonophobia) and migraine with aura (reversible focal neurological symptoms that develop over 5-20 minutes and last for less than 60 minutes); average at given month was calculated by dividing total number of migraine attacks until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
        <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Number of Monthly Migraine Attacks (According to the Diagnostic Criteria of the International Headache Society) at Month 1, 2, 3, 4, 5 and 6</title>
          <description>Migraine is a headache disorder with 2 subtypes: migraine without aura (at least 5 attacks lasting 4-72 hours with at least 2 following characteristics: unilateral location, pulsating quality, moderate/severe pain and either nausea/vomiting or photophobia and phonophobia) and migraine with aura (reversible focal neurological symptoms that develop over 5-20 minutes and last for less than 60 minutes); average at given month was calculated by dividing total number of migraine attacks until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Migraine attacks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.25"/>
                    <measurement group_id="O2" value="4.3" spread="2.94"/>
                    <measurement group_id="O3" value="4.2" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.60"/>
                    <measurement group_id="O2" value="-0.4" spread="2.92"/>
                    <measurement group_id="O3" value="-0.5" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.61"/>
                    <measurement group_id="O2" value="-0.7" spread="2.75"/>
                    <measurement group_id="O3" value="-0.7" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.56"/>
                    <measurement group_id="O2" value="-0.8" spread="2.71"/>
                    <measurement group_id="O3" value="-0.7" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.54"/>
                    <measurement group_id="O2" value="-0.9" spread="2.68"/>
                    <measurement group_id="O3" value="-0.8" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.56"/>
                    <measurement group_id="O2" value="-0.9" spread="2.69"/>
                    <measurement group_id="O3" value="-0.8" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.59"/>
                    <measurement group_id="O2" value="-0.9" spread="2.68"/>
                    <measurement group_id="O3" value="-0.8" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8762</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3031</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monthly Migraine Attacks (According to 48-Hour Rule) at Month 1, 2, 3, 4, 5 and 6</title>
        <description>As per 48-hour rule, if the symptom of pain due to migraine continues for more than 48 hours, it should be considered as 2 or more migraine attacks considering the maximum duration up to 48 hours. If the interval between the latest migraine attack (ending time) and the previous migraine attack (onset time) is less than 48 hours, the 2 migraine attacks should be considered as 1 migraine attack. If the onset of the migraine was prevented by a rescue drug, it should be considered as 1 migraine attack even if the aura had started.</description>
        <time_frame>Baseline (28 days before randomization), Month 1, 2, 3, 4, 5 and 6</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Migraine Attacks (According to 48-Hour Rule) at Month 1, 2, 3, 4, 5 and 6</title>
          <description>As per 48-hour rule, if the symptom of pain due to migraine continues for more than 48 hours, it should be considered as 2 or more migraine attacks considering the maximum duration up to 48 hours. If the interval between the latest migraine attack (ending time) and the previous migraine attack (onset time) is less than 48 hours, the 2 migraine attacks should be considered as 1 migraine attack. If the onset of the migraine was prevented by a rescue drug, it should be considered as 1 migraine attack even if the aura had started.</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Migraine attacks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.28"/>
                    <measurement group_id="O2" value="4.9" spread="1.52"/>
                    <measurement group_id="O3" value="5.1" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.94"/>
                    <measurement group_id="O2" value="-0.6" spread="2.28"/>
                    <measurement group_id="O3" value="-0.3" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.77"/>
                    <measurement group_id="O2" value="-0.8" spread="2.03"/>
                    <measurement group_id="O3" value="-0.6" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.73"/>
                    <measurement group_id="O2" value="-0.9" spread="1.95"/>
                    <measurement group_id="O3" value="-0.7" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.71"/>
                    <measurement group_id="O2" value="-1.0" spread="1.90"/>
                    <measurement group_id="O3" value="-0.7" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.72"/>
                    <measurement group_id="O2" value="-1.0" spread="1.91"/>
                    <measurement group_id="O3" value="-0.8" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.75"/>
                    <measurement group_id="O2" value="-1.0" spread="1.92"/>
                    <measurement group_id="O3" value="-0.8" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1145</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3971</p_value>
            <p_value_desc>Month 6: ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Migraine Attacks (According to 24-Hour Rule) Over Week 19 to Week 22 Period</title>
        <description>The change from baseline in average number of migraine attacks (as per 24-hour rule) over Week 19 to Week 22 period was calculated by subtracting the baseline value from the average value of the Week 19 to Week 22 period.</description>
        <time_frame>Baseline (28 days before randomization), Week 19 to Week 22 Period</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Migraine Attacks (According to 24-Hour Rule) Over Week 19 to Week 22 Period</title>
          <description>The change from baseline in average number of migraine attacks (as per 24-hour rule) over Week 19 to Week 22 period was calculated by subtracting the baseline value from the average value of the Week 19 to Week 22 period.</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Migraine attacks</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.28"/>
                    <measurement group_id="O2" value="-1.2" spread="0.28"/>
                    <measurement group_id="O3" value="-0.7" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1866</p_value>
            <p_value_desc>ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1507</p_value>
            <p_value_desc>ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Rescue Drug Treatment Days</title>
        <description>Rescue medications are administered to participants when efficacy of study drug is not satisfactory, or effect of study drug is too great and is likely to cause a hazard to participant, or to manage an emergency situation. If an aura of migraine, a migraine attack or a non-migraine headache attack occurred during the study period, use of following rescue drugs was permitted: analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), ergotamines, triptans and anti-emetics (drug used to stop vomiting). Average at baseline was calculated by dividing total number of rescue drug treatment days until baseline by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
        <time_frame>Baseline (28 days before randomization)</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Rescue Drug Treatment Days</title>
          <description>Rescue medications are administered to participants when efficacy of study drug is not satisfactory, or effect of study drug is too great and is likely to cause a hazard to participant, or to manage an emergency situation. If an aura of migraine, a migraine attack or a non-migraine headache attack occurred during the study period, use of following rescue drugs was permitted: analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), ergotamines, triptans and anti-emetics (drug used to stop vomiting). Average at baseline was calculated by dividing total number of rescue drug treatment days until baseline by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.21"/>
                    <measurement group_id="O2" value="5.7" spread="2.50"/>
                    <measurement group_id="O3" value="6.1" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Average Number of Rescue Drug Treatment Days at Month 6</title>
        <description>Rescue medications are medicines that may be administered to the participants when efficacy of study drug is not satisfactory, or the effect of study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation. If an aura of migraine, a migraine attack or a non-migraine headache attack occurred during the study period, use of following rescue drugs was permitted: analgesics, NSAIDs, ergotamines, triptans and anti-emetics. Average at Month 6 was calculated by dividing total number of rescue drug treatment days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
        <time_frame>Month 6</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Number of Rescue Drug Treatment Days at Month 6</title>
          <description>Rescue medications are medicines that may be administered to the participants when efficacy of study drug is not satisfactory, or the effect of study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation. If an aura of migraine, a migraine attack or a non-migraine headache attack occurred during the study period, use of following rescue drugs was permitted: analgesics, NSAIDs, ergotamines, triptans and anti-emetics. Average at Month 6 was calculated by dividing total number of rescue drug treatment days until that month by the total number of days of assessment, multiplied by 28 (a month was equal to 28 days).</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.21"/>
                    <measurement group_id="O2" value="-0.8" spread="0.21"/>
                    <measurement group_id="O3" value="-0.4" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1743</p_value>
            <p_value_desc>ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2165</p_value>
            <p_value_desc>ANCOVA method using the treatment group as the factor and using the value obtained during the baseline measurement period as the covariate was used.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response to Study Treatment</title>
        <description>Responders were the participants who had at least 50 percent reduction in the average number of monthly migraine attacks.</description>
        <time_frame>Month 1, 2, 3, 4, 5 and 6</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response to Study Treatment</title>
          <description>Responders were the participants who had at least 50 percent reduction in the average number of monthly migraine attacks.</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="20.8"/>
                    <measurement group_id="O3" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3083</p_value>
            <p_value_desc>Month 6</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percentage difference</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7235</p_value>
            <p_value_desc>Month 6</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percentage difference</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form-36 Health Survey (SF-36) Score</title>
        <description>The SF-36 is a survey of participant health. It consists of 8 scaled scores, which are weighted sums of the questions in their section. The 8 sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. Each item is scored on a 0-100 range so that total score ranges from 0-100 with high score indicating more favorable health state. Final evaluation was done at Day 155 or at discontinuation for those participants who discontinued before Day 155.</description>
        <time_frame>Baseline (28 days before randomization), Day 29, 85 and final evaluation (FE) (Day 155/early withdrawal [EW])</time_frame>
        <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization. Here 'n' signifies those participants who were evaluable for this measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Topiramate (JNS019) 50 mg</title>
            <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O2">
            <title>Topiramate 100 mg</title>
            <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form-36 Health Survey (SF-36) Score</title>
          <description>The SF-36 is a survey of participant health. It consists of 8 scaled scores, which are weighted sums of the questions in their section. The 8 sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. Each item is scored on a 0-100 range so that total score ranges from 0-100 with high score indicating more favorable health state. Final evaluation was done at Day 155 or at discontinuation for those participants who discontinued before Day 155.</description>
          <population>The FAS included all participants randomly assigned to study treatment excluding those who did not meet eligibility criteria, did not receive study treatment at all and did not provide any efficacy data after randomization. Here 'n' signifies those participants who were evaluable for this measure at given time points.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.59" spread="5.029"/>
                    <measurement group_id="O2" value="53.84" spread="8.267"/>
                    <measurement group_id="O3" value="54.17" spread="5.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.03" spread="6.459"/>
                    <measurement group_id="O2" value="53.15" spread="7.732"/>
                    <measurement group_id="O3" value="54.26" spread="5.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.86" spread="5.989"/>
                    <measurement group_id="O2" value="53.85" spread="7.160"/>
                    <measurement group_id="O3" value="54.47" spread="5.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning:FE (Day155/EW)(n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.02" spread="5.606"/>
                    <measurement group_id="O2" value="53.79" spread="7.643"/>
                    <measurement group_id="O3" value="54.40" spread="5.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.10" spread="9.529"/>
                    <measurement group_id="O2" value="45.29" spread="11.095"/>
                    <measurement group_id="O3" value="45.86" spread="9.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.49" spread="10.892"/>
                    <measurement group_id="O2" value="46.05" spread="11.094"/>
                    <measurement group_id="O3" value="46.35" spread="9.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.88" spread="9.687"/>
                    <measurement group_id="O2" value="46.34" spread="10.320"/>
                    <measurement group_id="O3" value="46.95" spread="9.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical: FE (Day 155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.21" spread="10.675"/>
                    <measurement group_id="O2" value="45.69" spread="10.384"/>
                    <measurement group_id="O3" value="46.29" spread="9.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.75" spread="8.822"/>
                    <measurement group_id="O2" value="41.76" spread="10.171"/>
                    <measurement group_id="O3" value="39.67" spread="9.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.98" spread="10.029"/>
                    <measurement group_id="O2" value="44.43" spread="10.352"/>
                    <measurement group_id="O3" value="41.17" spread="9.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.09" spread="9.450"/>
                    <measurement group_id="O2" value="44.43" spread="9.923"/>
                    <measurement group_id="O3" value="42.03" spread="8.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain: FE (Day 155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.64" spread="8.504"/>
                    <measurement group_id="O2" value="43.82" spread="9.906"/>
                    <measurement group_id="O3" value="42.87" spread="8.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.56" spread="8.444"/>
                    <measurement group_id="O2" value="48.92" spread="8.571"/>
                    <measurement group_id="O3" value="47.61" spread="7.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.30" spread="8.996"/>
                    <measurement group_id="O2" value="49.21" spread="9.176"/>
                    <measurement group_id="O3" value="49.12" spread="7.904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.48" spread="8.827"/>
                    <measurement group_id="O2" value="48.70" spread="9.857"/>
                    <measurement group_id="O3" value="49.31" spread="8.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health: FE (Day 155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.48" spread="8.459"/>
                    <measurement group_id="O2" value="48.12" spread="9.425"/>
                    <measurement group_id="O3" value="49.86" spread="8.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.91" spread="7.754"/>
                    <measurement group_id="O2" value="49.10" spread="7.765"/>
                    <measurement group_id="O3" value="49.17" spread="8.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.72" spread="8.888"/>
                    <measurement group_id="O2" value="47.59" spread="9.900"/>
                    <measurement group_id="O3" value="50.78" spread="8.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.45" spread="9.484"/>
                    <measurement group_id="O2" value="48.04" spread="9.375"/>
                    <measurement group_id="O3" value="49.40" spread="8.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality: FE (Day 155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.73" spread="9.625"/>
                    <measurement group_id="O2" value="47.66" spread="9.850"/>
                    <measurement group_id="O3" value="50.34" spread="8.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.62" spread="9.342"/>
                    <measurement group_id="O2" value="47.98" spread="10.108"/>
                    <measurement group_id="O3" value="47.82" spread="10.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.06" spread="10.178"/>
                    <measurement group_id="O2" value="46.25" spread="10.955"/>
                    <measurement group_id="O3" value="49.10" spread="9.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.89" spread="11.916"/>
                    <measurement group_id="O2" value="46.89" spread="10.454"/>
                    <measurement group_id="O3" value="49.10" spread="9.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning: FE (Day155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.81" spread="11.440"/>
                    <measurement group_id="O2" value="46.11" spread="11.475"/>
                    <measurement group_id="O3" value="49.01" spread="10.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.13" spread="7.916"/>
                    <measurement group_id="O2" value="51.22" spread="8.515"/>
                    <measurement group_id="O3" value="51.20" spread="8.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.82" spread="8.891"/>
                    <measurement group_id="O2" value="48.29" spread="10.837"/>
                    <measurement group_id="O3" value="51.69" spread="8.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.27" spread="9.126"/>
                    <measurement group_id="O2" value="49.72" spread="8.104"/>
                    <measurement group_id="O3" value="51.60" spread="7.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional: FE (Day 155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.38" spread="10.419"/>
                    <measurement group_id="O2" value="48.18" spread="9.941"/>
                    <measurement group_id="O3" value="50.80" spread="8.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health: Baseline (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.01" spread="7.632"/>
                    <measurement group_id="O2" value="50.34" spread="8.161"/>
                    <measurement group_id="O3" value="50.62" spread="8.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health: Day 29 (n=127,122,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.77" spread="8.793"/>
                    <measurement group_id="O2" value="46.33" spread="10.524"/>
                    <measurement group_id="O3" value="52.02" spread="8.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health: Day 85 (n=111,109,121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.87" spread="9.402"/>
                    <measurement group_id="O2" value="47.18" spread="9.669"/>
                    <measurement group_id="O3" value="51.11" spread="8.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health: FE (Day 155/EW) (n=130,130,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.48" spread="10.270"/>
                    <measurement group_id="O2" value="48.19" spread="9.648"/>
                    <measurement group_id="O3" value="51.14" spread="8.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topiramate (JNS019) 50 mg</title>
          <description>In titration period, topiramate 25 milligram (mg) tablet once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="E2">
          <title>Topiramate 100 mg</title>
          <description>In titration period, topiramate 25 mg tablet once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>In titration period, matching placebo tablet once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice daily orally from Day 22 to Day 28 and continued further for 18 weeks in the fixed dose period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J V11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Closed-angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureterodialysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/J V11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="130"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Group Manager</name_or_title>
      <organization>Janssen Pharmaceutical KK Japan</organization>
      <phone>+81-3-4411-5072</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

